Analysis of molecular targets and development into drug discovery for cyclic peptides possessing thrombolysis-enhancing action

2016 Fiscal Year Final Research Report

• Project/Area Number: 26350969
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Chemical biology
• Research Institution: Akita University
• Principal Investigator: KOIZUMI Yukio 秋田大学, 医学(系)研究科(研究院), 助教 (80353465)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 抗血栓薬 / 線溶系 / マルホルミン / RSK / ウロキナーゼ

Outline of Final Research Achievements

Treatment and prevention of thrombotic diseases such as cerebral infarction and myocardial infarction are extremely important. As a result of searching thrombolysis-enhancing substances using in vitro thrombolytic activity evaluation system, we have discovered cyclic pentapeptide malformin. The purpose of this study is to elucidate the mechanism of action for malformin. In this study, we showed that malformin induces the activation of RSK1, raises the expression of urokinase and promotes fibrinolytic activity via plasminogen activation in plasma fluid. From the results of this study, it is expected to create the next generation thrombolytic agent based on the molecular structure of malformin.

Free Research Field

ケミカルバイオロジー